REG - OptiBiotix Health - Launch of novel prebiotic in Europe and Africa

OptiBiotix HealthAnnouncement

26/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220926:nRSZ5247Aa&default-theme=true

RNS Number : 5247A  OptiBiotix Health PLC  26 September 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of novel prebiotic in Europe and Africa

New product will be branded OptiXOS

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease and diabetes, announces it
has signed an exclusive distribution agreement with Shandong Longlive
Biotechnology Co Ltd ("Longlive") for the distribution of Longlive's unique
xylooligosaccharide ("XOS") prebiotic into the human nutrition markets (foods
& beverages and supplements) in Europe and Africa. The product will be
branded OptiXOS.

 

Longlive is one of the global technology and market leader in the novel
prebiotic XOS. The company has a core capability in corn and corncob
processing into various food ingredients such as starch, polyols, sugar
replacers, monosaccharides and prebiotic fibres.

 

XOS is a prebiotic fibre with unique characteristics and benefits compared to
other prebiotic fibres commercially available in Europe. One gram of XOS is
sufficient to have a marked effect on the growth of healthy favourable gut
microbes such as bifidobacteria and lactobacilli. Its superior stability at
high temperatures and low pH combined with the small effective dose give it
wide applicability within food & beverage applications and extends its
reach to supplement applications requiring pills, tablets and capsules. XOS is
stable in the harsh environment of the gastrointestinal tract which maximises
its effectiveness when it reaches the gut.

 

XOS also has a complementary effect on the growth and propagation of
probiotics such as Lactobacillus plantarum and Lactobacillus rhmanosus (such
as LGG). This creates the potential for probiotic companies to boost the
health benefits of their existing products and create real differentiation in
the market. This application has been researched by OptiBiotix as part of a
joint development with DSM (announced 5 April 2016) and is covered by an
extensive patent portfolio.

 

Longlive has been successful in obtaining key regulatory approvals for XOS in
the North American market (FDA GRAS and New Dietary Ingredient, Health Canada)
and in 2018 obtained EFSA Novel Food approval opening up the European market.

 

OptiXOS comes with an active a pipeline of customer projects passed on by
Longlive and is commercially available to customers with immediate effect. The
new logo for the product is displayed below.

 

 

René Kamminga, CEO of OptiBiotix Limited, commented: "XOS is an important
addition to OptiBiotix's technology portfolio. It is a building block that
will increase our importance in microbiome modulation and act as leverage for
our more advanced science based prebiotic solutions in the food & beverage
and supplement industry in Europe & Africa. The agreement with Longlive is
another step for Optibiotix on its path to in-license or acquire unique
technologies to broaden its product portfolio and reinforce our role as
leaders in the microbiome field. We look forward to working with the team at
Longlive to make this link-up into a significant contributor to our mutual
business growth ambitions."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEWFMDEESEIU